April 09, 2021 Dropping aspirin soon after PCI seems to be the best strategy for preventing bleeding in high-risk patients with nonvalvular atrial fibrillation (AF), according to a landmark analysis of the RE-DUAL PCI trial. As reported by TCTMD, RE-DUAL PCI supported moving away from a triple-therapy strategy—P2Y12 inhibitor, warfarin, and aspirin—in these patients in order to lessen bleeding without increasing the risk of thrombotic events. The new data in conjunction with the rest of the available evidence, including those from AUGUSTUS, “are pretty clear that that strategy of prolonged triple therapy almost should never be used,” study co-author Deepak L. Bhatt, MD, MPH (Brigham and Women’s Hospital, Boston, MA), told TCTMD. “Our article sort of helps bring some granularity to the sort of minimum duration of aspirin that's probably needed.”